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Aim To compare benefits and costs of invasive versus medical management in elderly
patients with chronic angina.
Methods and results In a predefined subgroup of 188 patients of the Trial of Inva-
sive versus Medical therapy in Elderly patients with chronic angina (TIME), one-year
benefits were assessed as freedom from major events and improvements in symp-
toms and quality of live. Costs were determined as one-year costs of resource uti-
lisation. Invasive patients had higher 30-day, but lower months 2–12 hospital and
intervention costs than medical patients, resulting in somewhat higher one-year
costs for invasive management (p = 0.08). However, billing data available for a sub-
group of patients showed higher practitioner’s charges in the medical patients
(adjusted p = 0.0015).
Incremental costs to prevent one major event by invasive management averaged
CHF 10100 (95% CI: 800 to 28300) or € 6965, ranging from average CHF 5100
(€ 3515) to CHF 11600 (€ 8000) in a best, compared to a worst, case scenario.
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2196 J. Claude et al.Conclusions Early increased costs of revascularization in invasive patients were bal-
anced after one year by increased practitioners’ charges and symptom-driven late
revascularizations in medical patients. Therefore, the invasive strategy with im-
proved clinical effectiveness at only marginally higher costs as medical management
was cost-effective. Costs should not be an argument against invasive management of
elderly patients with chronic angina.c 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.Introduction
In times of health-economic constraints, analyses of new
treatment costs or new indications relative to observed
healthcare benefits become important, particularly if
such therapies are evaluated in the fastest growing pop-
ulation segment of elderly patients. This is certainly true
for the management of chronic symptomatic coronary ar-
tery disease (CAD) which is most prevalent in men and
women above the age of 75 years. Yet, even in younger
patients, no trial-based cost-effectiveness analyses of
percutaneous coronary interventions (PCI) relative to
medical therapy are available1 and only a few comparing
coronary artery bypass graft (CABG) surgery to medi-
cine.2–5 The latter studies suggested that CABG surgery
is most economically attractive when applied to high-risk
patients and those with severe symptoms.4
The Trial of Invasive versus Medical therapy in Elderly
patients (TIME) was the first randomized trial which com-
pared two treatment strategies in patients P75 years of
agewithchronicsymptomaticCAD.6 It showedthatan inva-
sive strategyusingcoronary angiography followedbyPCIor
CABG surgery, if feasible, was superior to optimised drug
therapy in reducing symptoms and improving measures of
quality of life (QoL) at the cost of a non-significant early
intervention hazard. After one year, treatment benefit
persisted but patients assigned to medical management
showed late improvements in symptom relief and well-
being in association with late revascularizations in almost
half of them.7 It was therefore concluded that patients
above the age of 75 years with chronic angina may choose
betweenanearly invasive strategywith early symptomatic
benefitatacertainsmall intervention riskandanoptimised
medical strategy with a 50% chance of late hospitalisation
andrevascularization.Notethatpatientswereselectedfor
the TIME study based on their clinical presentation and not
based on angiographic findings; thus, only 72% of invasive
treatment-assigned patients were in fact revascularized
whereas 46% of medical treatment-assigned patients
needed revascularization during follow-up.
In view of themagnitude of the concerned patient pop-
ulation, the implementation of such study results into
treatment guidelines may induce a relevant health-eco-
nomic burden. This prospect may make responsible
doctors reluctant today to apply such a strategy to 80-
year-old patients. However, the TIME study offered the
opportunity not only to assess the relative clinical benefits
of both treatment strategies but also the relative costs
and, on that basis, to perform a formal cost-effectiveness
analysis. The aim of the present substudy, therefore, wasto compare relative benefits and costs of both treatment
strategies in a pre-specified representative subgroup of
TIME patients over a one year period. The hypothesis was
that the increased clinical effectiveness of the invasive
strategy would be paralleled by increased costs.Methods
In the prospective Swiss multi-centre TIME study, patients aged
75 years or older with chronic angina pectoris of Canadian Car-
diac Society classP II, despite at least 2 anti-anginal drugs,
were randomized to a strategy of optimised medical therapy
(MED) or an invasive strategy (INV) with coronary angiography
followed by PCI or CABG surgery if feasible. The primary end-
point was QoL assessed by standardised questionnaires and
freedom from major adverse clinical events (MACE): death,
non-fatal myocardial infarction or hospitalisation for uncon-
trolled symptoms/acute coronary syndrome with or without
need for revascularization. Patients were excluded mainly for
acute myocardial infarction within the previous 10 days, con-
comitant valvular or other heart disease, predominant conges-
tive heart failure and no consent for a possible
revascularization procedure. Details of the TIME study have
been reported previously.6 After collection of baseline data,
QoL was assessed by self-administered questionnaires including
the Short Form 36 (SF36),8 the Duke Activity Status Index
(DASI9), the Rose angina questionnaire10 and questions about
education and socioeconomic status. In all surviving patients,
the same evaluations of clinical and QoL status were performed
after 6 and 12 months. The study was approved by the Ethics
Committee of the Swiss Academy of Medical Sciences and by
the local Ethics Committees of each of the 14 Swiss centres.
Patients gave written informed consent.
Patients
For the present cost-effectiveness analysis, all 188 patients of 4
hospitals of Northern Switzerland were included (62% of the to-
tal TIME population), i.e. patients from only two Swiss cantons
with a similar health care system and common insurance compa-
nies. Note that in Switzerland, all patients have statutory health
care insurance, but type of insurance and health plans vary con-
siderably between cantons and insurance companies. Baseline
characteristics and outcome parameters were compared to the
total TIME population (n = 301) to document the representativity
of the subgroup.Assessment of costs
Reliable healthcare related cost estimates are difficult to obtain
in Switzerland. There are few real cost data and no large admin-
istrative databases allowing for an easy access to claims data. In
Table 1 Parameters of cost calculation
Unit Cost/unit (CHF) (€)
Hospital stay (1 day) 650 345
Intensive care (1 day) 3000 1380
Coronary angiography 2800 1931
PCI 4800 3310
CABG 11000 7586
Stress echocardiography 750 517
Stress scintigraphy 750 517
Cost-effectiveness in elderly CAD patients 2197this situation, a double approach to cost assessment was
adopted. First, inpatient resource use was prospectively re-
corded over the one year observation period of the TIME trial.
It was valued by unit cost estimates derived from the official
Swiss medical tariff system (TARMED), taking into account local
particularities (Table 1).11 These cost estimates are available for
all 188 patients of both treatment groups included in this sub-
study. Resources taken into account include hospital days
(intensive care separated from general ward) as well as invasive
and major non-invasive procedures relating to CAD.
Secondly, all involved third party payers were asked to
provide information on their insured total health care
charges over the one-year study period. Four insurance com-
panies collaborated and a total of 56 patients gave their spe-
cial written informed consent thus forming the basis for an
analysis of patient-level medical claims data. To calculate
in- and outpatient charges, all claims from hospital stays,
private physician visits as well as visits to cardiologists, angi-
ologists and neurologists, pharmacy claims and claims of
rehabilitation services were collected over the one-year study
period.
We refer to the results of the first-mentioned approach as
costs and used them for the base case calculation of cost-effec-
tiveness. The results of the second-mentioned approach are re-
ferred to as charges and were used in the sensitivity analysis as
described below.Assessment of cost-effectiveness
Detailed clinical effectiveness results have been published pre-
viously for the total TIME population6,7; the results presented
here relate to the subgroup of 188 TIME patients with available
cost data. Incremental clinical effectiveness, the denominator
in the cost-effectiveness equation, was expressed as the differ-
ence between the INV compared to MED treatment groups in
terms of event-free survival and in terms of global QoL over
time. The study was not powered to detect a mortality differ-
ence and such a difference was not found; therefore, measures
of QoL assessed by standardized questionnaires and as freedom
from major non-fatal events were main determinants of effec-
tiveness despite the fact that hospitalisations also appear on
the cost side of the cost-effectiveness equation. To estimate a
summary measure of global QoL over the entire study period,
utilities were computed from SF36-scores12 collected at inclu-
sion, and after six and twelve months. Utilities at critical events
were assumed to be the minimum of the two utilities assessed at
the beginning and the end of the respective six-month period.
For all other time points, utilities were estimated by linear
interpolation. The utility value of the third assessment was car-
ried forward until the end of the one-year period whenever this
assessment occurred earlier. The average utility over the one
year study period was then computed as the area under the
polygonal line resulting from this procedure, ‘0’ representing
death and ‘1’ optimal health.Incremental cost-effectiveness was calculated as the incre-
mental cost required to prevent one major adverse event and
as the incremental cost to improve the average utility during
the first year among survivors.Statistics
All data were analysed based on the intention-to-treat princi-
ple. Data on costs and charges are presented in Swiss currency
CHF; (1 Euro @ 1.45 CHF). Data on costs and charges are sum-
marized by mean values and their standard errors and by the
three quartiles. With count variables, the maximum is given
in addition. Differences in means of cost-related variables
(including the number of hospital days per patient and the indi-
vidual frequencies of different types of interventions) and of
event rates between the two treatment arms were assessed
using bootstrap t-tests. On the other hand, differences in
QoL scores, numbers of anti-anginal drugs and in quantitative
baseline variables between the two groups were assessed using
the Wilcoxon–Mann–Whitney test as previously described.6
Differences in survival curves between groups were assessed
using the log-rank test and hazard ratios were estimated by
Cox-regression. All p-values reported in tables and figures are
two-sided. For additive components of a major variable, Bon-
ferroni-adjusted values are given (Tables 3–5, Fig. 2). In order
to differentiate between early (intervention-related for inva-
sive patients) and follow-up costs, we separated costs accumu-
lated during the first 30 days from those accumulated between
days 31 and the end of the one year follow-up. Bootstrap tech-
niques were used to estimate 95% confidence intervals (95% CI)
for differences in average costs and effect measures (i.e. num-
ber of MACE, number of days without MACE, utility score) and
for the incremental cost-effectiveness ratios presented (each
of these simulations using 50000 replicate13), and also to as-
sess the shape of the joint sampling distribution of the differ-
ences in average individual costs and effects between the two
treatment groups (with 5000 replicate per simulation). Pre-
senting cost-effectiveness results as ratios with 95% confidence
intervals is insufficient, as their interpretation depends on the
quadrants of the cost-effectiveness plane (CE plane) into which
they fall.14 For example, in the assessment of a less efficient,
but cheaper new treatment strategy (represented in the lower
left quadrant of the CE plane), a numerically high cost-effec-
tiveness ratio would be favorable, whereas in the familiar sit-
uation of a more expensive, but more efficient strategy (upper
right quadrant), the opposite is true.14 The remaining quad-
rants represent situations where the evaluated strategy is more
expensive and less effective (dominated; upper left quadrant)
or less expensive and more effective (dominant; lower right
quadrant). This is taken into account by an additional graphical
representation of the bootstrapping results in the CE plane,
with 95%- and 50%-confidence ellipses describing their degree
of uncertainty.Sensitivity analysis
Uncertainty is present in the effectiveness and resource use
results as well as in the unit cost estimates used for cost-
effectiveness calculation. Uncertainty in the two first-men-
tioned entities is of a stochastic nature and covered by the
probabilistic methods described in the statistics section. But
uncertainty in unit cost estimates required additional sensitiv-
ity analyses. To this effect, bootstrapping procedures were re-
peated with unit costs varied according to a best case and a
2198 J. Claude et al.worst case scenario based on the observed variation of pa-
tient-specific charges available for 56 patients. The bound-
aries of the non-parametric 99% confidence interval of
individual charge-to-cost-ratios were multiplied by the base
case unit cost estimates to determine the range of unit cost
variation.Results
Baseline characteristics
Baseline characteristics of the study group (n = 188)
subdivided into the two treatment strategies, INV and
MED, are shown in Table 2. There were no significant
differences between these groups at baseline. Neither
were there significant differences between the total
study group of 188 patients and the complementary
TIME population not included in this cost analysis
(n = 113), nor did the subgroup with data concerning
charges (n = 56) differ from the complementary sub-
group of 132 patients considered in the present analysis
(data not shown). This was true for clinical data as well
as measures of QoL.Table 2 Baseline characteristics
Medical
n 94
Age (years) 79.5 ± 3.3
Women (%) 44
Prior infarction (%) 59
Prior revascularization (%) 22
P2 risk factors (%) 53
P2 co-morbid illnesses (%) 21
Angina class 3–4 (%) 75
Anti-anginal drugs (number) 2.5 ± 0.7
Non-invasive LVEF (%) 51.4 ± 13.0
Multi-vessel disease (%) –
Table 3 One year outcome (events per patient and number of de
MEDa
n 94
Deaths 5 (5.3%)
Non-fatal infarctions/patient 0.20 ± 0.049
(0/0/0/2)
Deaths/infarctions/patient 0.26 ± 0.052
(0/0/0/2)
Hospitalisations without revascularization/patient 0.22 ± 0.053
(0/0/0/2)
Hospitalisations with revascularization/patient 0.52 ± 0.064
MACE/patient 1.0 ± 0.104
(0/1/1/5)
a Mean value ± SEM, in parentheses: 25th, 50th, 75th percentile and maxim
b Assessed using Fisher’s exact test.
c Assessed using the bootstrap t-test.
d p-value = 0.09.
e p-value <0.0003 with Bonferroni adjustment accounting for the fact that t
hosptalisations without revascularization and hospitalisations with revasculaEffectiveness
One year outcome of the study group (Table 3) was
similar to that of the total TIME population. MACE oc-
curred significantly less frequently in INV as compared
to MED patients (0.38 per INV patient versus 1.0 per
MED patient, p < 0.0001, corresponding to 23% INV pa-
tients with MACE versus 65% MED patients with MACE,
p < 0.0001), although the rate of death or non-fatal
myocardial infarction was similar for both groups after
one year (0.20 per INV patient, 0.26 per MED patient,
p = 0.29). The same trend towards an early intervention
hazard regarding mortality noted in the overall trial5
was observed in the cost substudy population with a
hazard ratio of 2.18 (95% CI: 0.74–6.38; p = 0.16).
The benefit in MACE over time used for the present
cost-effectiveness analysis is shown graphically in Fig.
1 as shaded area between the two event-free survival
curves. There was a significant reduction in angina
severity and improvement in measures of QoL for both
treatment groups versus baseline after 6 and 12 months
but the difference between the two treatment groups
observed after 6 months was reduced after 12 months
due to 52% of MED patients needing revascularization
during follow-up. The benefit of INV versus MED man-Invasive Complementary TIME patients
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Fig. 1 Survival without MACE for INV (dotted line) versus MED patients (solid line). The shaded area in between represents the benefit of INV
management over time, i.e. the average gain in event-free time after inclusion. The relatively low number of patients at risk at day 360 are due to many
one year controls before that day censored in this figure.
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was again similar to the main trial: greater improve-
ment in INV patients during early months but no longer
significant differences after one year (data not shown).
In addition, angina severity as measured by the Rose
score improved significantly earlier and more persis-
tently in INV as compared to MED patients (p < 0.02)
and therefore, the number of anti-anginal drugs per pa-
tient was significantly lower after one year on INV ther-
apy (1.3 ± 1.0 (quartiles 0.5/1/2) versus 2.1 ± 1.3
(quartiles 1/2/3) drugs in MED patients, p < 0.0001).Costs and charges
Resource use results are shown in Table 4. Themean num-
ber of hospital days per patient at baseline was larger inTable 4 Study related resource use over one year (units per patie
Medicala
n 94
Hospital days/patient
Baseline 7.0 ± 1.22
(0/1/10/76)
Follow-up 14.6 ± 2.16
(0/8/20/118)
Total 21.6 ± 2.67
(3/15/28/146)
Coronary angiographies/patient 0.63 ± 0.071
(0/1/1/3)
PCI/patient 0.29 ± 0.062
(0/0/0/3)
CABG/patient 0.26 ± 0.045
(0/0/1/1)
Noninvasive tests/patient 0.35 ± 0.056
(0/0/1/2)
a Mean value ± SEM, in parentheses: 25th, 50th, 75th percentile and maxim
b Assessed using bootstrap t-test.
c p-value <0.0006 each with Bonferroni adjustment accounting for the fact t
of the average individual numbers of six 6 units: hospital days, ICU-days, cothe INV as compared to the MED group (p = 0.04, Bonfer-
roni-adjusted) because many MED patients remained
ambulatory throughout. During follow-up, INV patients
had less hospital days on average (p = 0.05) resulting in
a similar total hospital stay per patient of 19.4 days for
INV and 21.6 days for MED patients, respectively
(p = 0.53). Coronary angiography and PCI were used more
frequently in INV than in MED patients (p < 0.0006, Bon-
ferroni-adjusted) but CABG surgery was used similarly
in both groups although at much lower rates than PCI.
Overall, total costs per patient, i.e. including costs for
non-invasive tests, were only marginally higher in INV as
compared to MED patients: CHF 27580 (mean) ± 2088
(SEM) versus 22176 (mean) ± 2264 (SEM) per patient
(p = 0.08), the quartiles being 13850/21550/34500 and
3900/19675/31350, respectively. Thus, INV patients
had higher 30 day costs (CHF 21065 ± 1299 versusnt)
Invasivea p-valueb unadjusted
94
10.6 ± 0.95 0.02
(4/8/15/66)
8.7 ± 2.08 0.05
(0/0/7/100)
19.42.34 0.53
(7/11/22/113)
1.12 ± 0.037 <0.0001c
(1/1/1/3)
0.72 ± 0.067 <0.0001c
(0/1/1/3)
0.30 ± 0.047 0.52
(0/0/1/1)
0.46 ± 0.065 0.22
(0/0/1/2)
um.
hat the average total cost per subject was computed as a weighted sum
ronary angiographies, CABG, PCI and non-invasive tests.
2200 J. Claude et al.8479 ± 1481; p < 0.0002, Bonferroni-adjusted) but lower
months 2–12 follow-up costs than MED patients (CHF
6515 ± 1580 versus 13697 ± 1722; p = 0.004 Bonferroni-
adjusted) as shown in Fig. 2.
Detailed results of patient-specific charges in the
subgroup of 56 patients with these data are given in
Table 5. Besides more hospitalisations during follow-
up as noted above, MED patients had also significantly
more practitioners’ charges: MED patients consulted
their private physicians on average ten times more
frequently than INV patients during the first month
of the study and three times more often during the
following 11 months. Thus, and in contrast to totalFig. 2 Average costs (bars) with standard errors (whiskers) for both treatm
months 2–12 and for the entire one year period. Note the early increased co
strategy.
Table 5 Mean patient-specific charges over one year
Medicala
n 28
General practitioner 1404 ± 299
(0/949/2451)
Specialist 967 ± 277
(0/297/1059)
Pharmacy 2208 ± 479
(664/1454/2889)
Hospitalisation 24720 ± 6165
(4609/13388/25056)
Rehabilitation 2772 ± 752
(0/0/5610)
Total charges 32070 ± 6791
(9517/20530/37130)
a Charges in CHF: mean value ± SEM, 25th, 50th and 75th percentile (in par
b Assessed using bootstrap t-test.
c p-value 0.0015 with Bonferroni adjustment accounting for the fact that
subcategories.cost results, mean total charges per patient were
marginally lower for INV patients: CHF 26220 versus
32070 for MED patients, the medians being CHF
19986 versus CHF 20530 (p = 0.47). These results were
not significantly altered if patients who died during
follow-up were excluded from the analyses of costs
and charges.Cost-effectiveness
Over the one year study period, 0.61 (95% CI: 0.35–0.87;
p < 0.0001) major events per patient were prevented atent strategies (INV = grey, MED = white) during the first 30 days, during
sts of the INV strategy compared to the late increased costs of the MED
Invasivea p-valueb unadjusted
27
208 ± 111 0.0003c
(0/0/0)
1299 ± 230 0.37
(129/1210/2031)
2176 ± 400 0.96
(481/1692/3833)
20678 ± 3228 0.57
(9454/13168/31658)
1859 ± 645 0.36
(0/0/4590)
26220 ± 3520 0.47
(13543/19986/40173)
entheses).
the total charges are the sum of the total charges of the five given
4%
96%
Fig. 3 Bootstrap results (5000 replicates) for incremental cost-effectiveness, i.e. costs associated with the average number of MACE prevented, of INV
versus MED treatment. The outer ellipse represents the 95%-confidence region for the true incremental cost-effectiveness of INV as compared to MED
treatment. The inner ellipse defines the 50%-confidence region. The center of the ellipse represents the point estimate of incremental effects and costs,
i.e. 0.61 MACE prevented with CHF 5404 per patient.
1% 17%
73%9%
Fig. 4 Bootstrap results (5000 replicates) for incremental cost-effectiveness, i.e. costs associated with the average individual gain in utility, in the first
year among survivors with complete information on QoL according to SF36 (n = 66 and 58 for MED and INV patients, respectively). The outer ellipse
represents the 95%-confidence region for the true incremental cost-effectiveness of INV as compared to MED treatment. The inner ellipse defines the
50%-confidence region. The center of the ellipse represents the point estimate of incremental effects and costs, i.e., 0.024 utility units gained with CHF
3120 per patient.
Cost-effectiveness in elderly CAD patients 2201an average cost of CHF 5404 (95% CI: 640 to +11450;
p = 0.08) per patient managed invasively compared to
one on medical strategy (Fig. 3). This is equivalent to
an average incremental cost to prevent one major clini-
cal event of CHF 10100 (95% CI: 800 to +28300;
p = 0.08) or € 6965. The incremental cost per day without
MACE averaged CHF 68, corresponding to € 47; the aver-
age incremental cost to postpone the first major event
by an average of 91 days (95% CI: 53–129; p < 0.0001)
was CHF 5404 or € 3730. In Fig. 3, the datapoints repre-
senting bootstrapping results are contained in the upper
right (96%) and lower right (4%) quadrants of the CE
plane, indicating a higher effectiveness of the INV strat-
egy at higher costs, with a small possibility of a higher
effectiveness at lower costs.
Despite the significant benefit in angina severity and
reduction in anti-anginal therapy, the difference in util-
ities between the two treatment groups based on the
SF36 assessment was small: 0.024 (95% CI: 0.013 to0.061; p = 0.2) at an average cost of CHF 3120 or €
2152 per patient and year (Fig. 4). The majority of data
points is again situated in the upper right quadrant of the
cost-effectiveness plane, but there are points in all four
quadrants, indicating a more indifferent situation.
Results of sensitivity analyses showed that for the
worst case scenario, an increased incremental cost-
effectiveness ratio of CHF 11600 (95% CI: 900 to
32500) or of € 8000. In the best case scenario, this value
decreased to CHF 5100 (95% CI: 400 to 14200) or to €
3515.Discussion
This pre-defined cost-effectiveness analysis of the TIME
study shows that an invasive strategy in elderly patients
with angina pectoris refractory to standard drug therapy
2202 J. Claude et al.is cost-effective over a one-year observation period.
Costs and charges were not significantly higher for the
INV as compared to the MED strategy over this time per-
iod and there was a significant benefit of INV over MED
therapy regarding freedom from MACE as well as regard-
ing angina reduction. In the base case analysis, incre-
mental costs to prevent one additional major event
were in the range of CHF 10000 (€ 6900) which is small
compared to the incremental costs of other treatments
preventing life-threatening events.1 The accompanying
confidence interval, taking into account random varia-
tion in effectiveness and resource use results was even
crossing the zero line towards a situation of higher effec-
tiveness at lower costs.
Early costs of revascularization in the severely symp-
tomatic patients studied in TIME were offset by late costs
in medical therapy-assigned patients: increased rate of
late symptom-driven revascularization and increased
costs of private physician visits pointing towards a rele-
vant shift of costs based on the type of care delivered
to INV and MED patients. Thus, costs of revascularization
should not be a reason to withhold an invasive strategy to
elderly patients with chronic angina despite standard
medical therapy.
Previous cost-effectiveness analyses comparing CABG
surgery with medical therapy concluded that CABG sur-
gery has a highest cost-effectiveness ratio in high risk pa-
tients in whom surgery improves survival.2–4 In patient
subsets where mortality is not reduced, CABG surgery is
cost-effective only if symptoms are severe.4 These find-
ings are confirmed by the present analysis in patients
with symptoms refractory to usual drug therapy,
although only a minority of them were revascularized
by CABG surgery. Most patients (72%) were revascular-
ized by PCI as in the Angioplasty Compared to MEdicine
(ACME),15 the Second Randomized Intervention Treat-
ment of Angina (RITA-2)16 or the Atorvastatin VErsus
Revascularization Treatments (AVERT)17 trials. In none
of these trials were formal cost-effectiveness analyses
performed.1 They all included relatively low risk patients
with mild to moderate symptoms and a suitable anatomy
for PCI. Whereas the increased early costs of PCI dimin-
ished progressively during the longer-term follow-up in
the ACME trial,18 this was not the case in the RITA-2
trial.19 These differing results of RITA-2 which contrast
also to the present findings of the TIME study may be ex-
plained by a low stent use in RITA-2 inducing increased
rates of peri-procedural infarctions and repeat interven-
tions, a very low revascularization rate during follow-up
in medically treated patients (20%/3 years versus 46%/1
year in TIME) reflecting the mild symptoms of patients
in RITA-2 and the restricted intervention use in the Uni-
ted Kingdom. Outpatient visits and costs in medical pa-
tients of RITA-2 were similar in both treatment groups
but markedly increased in TIME patients, again most
likely due to the more severe symptoms of TIME patients.
Therefore, the differences in costs, and cost-effective-
ness, between these studies may be explained by patient
selection (severity of symptoms) and procedural differ-
ences (the mode of revascularization). Thus, the finding
of the present analysis indicates that revascularization iscost-effective if patients are severely symptomatic, just
as has been described for CABG surgery.4
In elderly patients, the rate of complications and the
length of hospital stay increases after CABG surgery20 as
well as after PCI.21 Retrospective comparative analy-
ses22,23 in relatively small groups of patients suggested
that the benefit of revascularization in elderly symptom-
atic patients tends to be greater and, therefore, cost-
effectiveness is increased. The present analysis of the
first prospective revascularization versus medical man-
agement trial in elderly patients confirms these observa-
tions in a formal cost-effectiveness analysis. We used
freedom of MACE and improvement in QoL as measures
of effectiveness as we defined QoL – and not survival
– as the primary endpoint of this trial with 80-year-old
patients. This has limitations however because hospital-
isations formally appear on both sides of the cost-
effectiveness equation. We have hypothesized on the
relative benefit of death, infarction and hospitalizations
on outcome in the TIME study before.7 The same limita-
tions are relevant and have been discussed for such anal-
yses after angioplasty and stenting23–25 and recently for
the economic evaluation of drug-eluting stents.26 They
should help to provide policymakers with a meaningful
and comparative ratio of different treatments despite
the fact that they do not primarily affect survival.
QoL was expressed in terms of an estimated mean
utility summarising assessments after 6 and 12 months
compared to baseline and the development over time.
However, QoL was not assessed at the point in time of
major events where utilities would have been lowest.
Therefore, estimated average utilities over one year
likely did not fully capture the actual difference in QoL
benefit (as suggested by the significant difference in
MACE in favor of INV management). In addition, anti-
ischaemic therapy aimed at reduction in angina is re-
flected in only one of the eight domains of the SF36 from
which utility values were derived. In addition, the differ-
ences in angina severity and number of anti-anginal drugs
needed could not be incorporated in the present cost-
effectiveness calculation. If these factors could have
been included in the formal incremental cost-effective-
ness analysis regarding QoL, the results would have fa-
vored the INV strategy even more.Conclusions
The findings of this pre-defined cost-effectiveness analy-
sis of elderly patients with chronic angina refractory to
standard drug therapy show that an invasive strategy
with coronary angiography followed by revascularization
if feasible is cost-effective over a one-year observation
period relative to optimised medical therapy. The early
increased costs of revascularization are balanced by in-
creased private practitioner’s charges and symptom-
driven late revascularizations. This suggests that an
invasive strategy with improved clinical effectiveness
at only marginally increased costs over one year, com-
pared to optimised medical management, may even be
Cost-effectiveness in elderly CAD patients 2203considered a ‘preferred’ strategy. Thus, increased inter-
vention costs should not be an argument to withhold an
invasive strategy to an elderly patient with symptomatic
chronic CAD. These conclusions are relevant to elderly
patients presenting to their private physicians for angina
refractory to standard anti-anginal therapy as was the
case with participants of the TIME study.Acknowledgements
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